Literature DB >> 25997105

Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.

Simone Longhi1, Candida Cristina Quarta, Agnese Milandri, Massimiliano Lorenzini, Christian Gagliardi, Lisa Manuzzi, Maria Letizia Bacchi-Reggiani, Ornella Leone, Alessandra Ferlini, Antonio Russo, Ilaria Gallelli, Claudio Rapezzi.   

Abstract

BACKGROUND: Although atrial fibrillation (AF) is a known complication of amyloidotic cardiomyopathy (AC), a precise pathophysiological and prognostic characterization is not available. We therefore aimed to assess prevalence, incidence, risk factors and prognostic significance of AF in light-chain (AL), hereditary transthyretin-related (m-ATTR) and non-mutant transthyretin-related (wt-ATTR) AC.
METHODS: Retrospective study of 262 patients with AC (123 AL, 94 m-ATTR, 45 wt-ATTR) from a single center.
RESULTS: AF prevalence was 15% (AL 9%, m-ATTR 11%, wt-ATTR 40%). During a median follow-up of 1.2 years 11 patients developed AF (2.1% person-years). Age, heart failure (HF), left ventricular (LV) ejection fraction, renal involvement, left atrial size and right atrial pressure were independently associated with AF. AF was associated with incident HF but not with increased mortality. All AF patients were prescribed warfarin and none suffered thromboembolic events.
CONCLUSIONS: In AC the prevalence of AF varies widely according to etiology with a mean value of 15% that reaches 40% in wt-ATTR amyloidosis. Age, HF, LV ejection fraction, left atrial size and right atrial pressure were the main independent risk factors, while wall thickness and etiology were not the main independent risk factors. AF does not seem to impact all-cause mortality but was strongly associated with prevalent and incident HF.

Entities:  

Keywords:  Amyloidosis; atrial fibrillation; cardiomyopathy; heart failure

Mesh:

Substances:

Year:  2015        PMID: 25997105     DOI: 10.3109/13506129.2015.1028616

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  27 in total

1.  The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution.

Authors:  M Arun; D Brauneis; G Doros; A C Shelton; J M Sloan; K Quillen; F L Ruberg; V Sanchorawala; C Varga
Journal:  Bone Marrow Transplant       Date:  2017-07-24       Impact factor: 5.483

Review 2.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

3.  Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

Authors:  Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

Review 4.  Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Florint Kroi; Nils Fischer; Ana Gezin; Mahmoud Hashim; Mark Hermannes Rozenbaum
Journal:  Cardiol Ther       Date:  2020-12-14

5.  Tc-99m pyrophosphate left atrial uptake in patients with atrial fibrillation and cardiac amyloidosis.

Authors:  Rami M Abazid; Jonathan G Romsa; James C Warrington; Robert Z Stodilka; Ryan A Davey; Sabe De; David L Laidley; William C Vezina; Cigdem Akincioglu
Journal:  J Nucl Cardiol       Date:  2021-01-27       Impact factor: 3.872

Review 6.  Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

7.  Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding.

Authors:  Lindsey R Mitrani; Jeffeny De Los Santos; Elissa Driggin; Rebecca Kogan; Stephen Helmke; Jeff Goldsmith; Angelo B Biviano; Mathew S Maurer
Journal:  Amyloid       Date:  2020-08-19       Impact factor: 7.141

Review 8.  Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Authors:  Lily K Stern; Michelle M Kittleson
Journal:  Curr Oncol Rep       Date:  2021-03-16       Impact factor: 5.075

9.  Cardiac Amyloidosis with Discordant QRS Voltage between Frontal and Precordial Leads.

Authors:  Csilla-Andrea Eötvös; Roxana-Daiana Lazar; Iulia-Georgiana Zehan; Erna-Brigitta Lévay-Hail; Giorgia Pastiu; Mihaela Pop; Anca Simona Bojan; Sorin Pop; Dan Blendea
Journal:  Medicina (Kaunas)       Date:  2021-06-27       Impact factor: 2.430

10.  Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients.

Authors:  Niklas Wange; Intissar Anan; Bo-Göran Ericzon; Johanna Pennlert; Björn Pilebro; Ole B Suhr; Jonas Wixner
Journal:  Transplantation       Date:  2018-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.